Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

• Status: Completed
• Trial end date: 2016-02-26

Summary

A Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination with Metformin in Chinese Subjects in China with Type 2 Diabetes Who Have Inadequate Glycaemic Control on Insulin Alone or on Insulin in Combination with Metformin

• Phase: Phase 3

Details

• Lead Sponsor: AstraZeneca
• Treatments: Insulin; Insulin, Globin Zinc; Insulin, Short-Acting; Metformin; Saxagliptin